Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 435 of the 436 references it cites were found in a registry or an index; none of the 356 sources its claims cite is checked for support yet.

2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Open access

Abstract

Author(s): Arnett, Donna K; Blumenthal, Roger S; Albert, Michelle A; Buroker, Andrew B; Goldberger, Zachary D; Hahn, Ellen J; Himmelfarb, Cheryl Dennison; Khera, Amit; Lloyd-Jones, Donald; McEvoy, J William; Michos, Erin D; Miedema, Michael D; Muñoz, Daniel; Smith, Sidney C; Virani, Salim S; Williams, Kim A; Yeboah, Joseph; Ziaeian, Boback

Overview

CoChat Summary

TL;DR

The 2019 ACC/AHA guideline provides evidence-based recommendations for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults, emphasizing healthy lifestyle, team-based care, risk estimation, and selective pharmacotherapy. It recommends 10-year ASCVD risk estimation for adults 40 to 75 years of age, statin therapy for high-risk groups, a general blood pressure target of <130/80 mm Hg, and infrequent routine aspirin use.

Key findings

  • The Top 10 take-home messages state that the most important way to prevent ASCVD, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life; team-based care is effective; and adults 40 to 75 years of age should undergo 10-year ASCVD risk estimation and a clinician–patient risk discussion before starting antihypertensive therapy, a statin, or aspirin.
  • Lifestyle recommendations include a diet emphasizing vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish while minimizing trans fats, red and processed meats, refined carbohydrates, and sweetened beverages; adults should engage in at least 150 minutes per week of accumulated moderate-intensity or 75 minutes per week of vigorous-intensity physical activity.
  • For adults with type 2 diabetes mellitus, lifestyle changes are crucial; if medication is indicated, metformin is first-line, followed by consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist. All adults should be assessed for tobacco use at every healthcare visit and advised to quit; aspirin should be used infrequently for routine primary prevention because of lack of net benefit; statin therapy is first-line for LDL-C ≥190 mg/dL, diabetes in adults 40 to 75 years of age, or sufficient ASCVD risk; and blood pressure target should generally be <130/80 mm Hg.
  • Cited evidence includes the PREDIMED trial, in which a Mediterranean diet supplemented with extra-virgin olive oil or nuts showed 30% and 28% reductions, respectively, in the combined endpoint of myocardial infarction, stroke, or cardiovascular mortality, driven largely by stroke reduction; and a UKPDS metformin substudy showing a 32% reduction in microvascular and macrovascular diabetes-related outcomes, a 39% reduction in myocardial infarction, and a 36% reduction in all-cause mortality.

Methods

  • This is an ACC/AHA clinical practice guideline developed by a writing committee; evidence searches were conducted between May and July 2018 in Ovid MEDLINE, PubMed, Cochrane Library, National Institute for Health and Care Excellence, and other selected databases.
  • The evidence review evaluated randomized controlled trials, systematic reviews of RCTs, meta-analyses, large US-based high-quality cohort studies, and observational studies across 9 topic areas: risk assessment, diet, exercise/physical activity, obesity and weight loss, type 2 diabetes mellitus, blood cholesterol, hypertension, smoking cessation, and aspirin use.
  • Recommendations were assigned Class of Recommendation and Level of Evidence, with a modified Delphi process used to reach consensus; recommendations for cardiovascular risk, blood cholesterol, and high blood pressure were adapted from the 2017 Hypertension Clinical Practice Guideline and the 2018 Cholesterol Clinical Practice Guideline. The document was reviewed by 5 official reviewers, 3 reviewers on behalf of societies, and 23 individual content reviewers, and approved by the ACC and AHA.

Limitations

  • The paper states that the pooled cohort equations have been shown to overestimate or underestimate ASCVD risk for certain subgroups; risk estimation is imperfect and based on group averages applied to individual patients; and cost/value assessments face methodological challenges including variability in costs and benefits across settings and subgroups, variability over time, and discounting that disadvantages prevention.
  • The paper states evidence gaps for aspirin in adults <40 or >70 years of age, for electronic nicotine delivery systems as tobacco treatment, for reducing sedentary behavior, and notes that the cardiovascular nutrition literature is limited by a paucity of large-scale prospective randomized trials with ASCVD outcomes.
  • Evident from the text: this guideline synthesizes and adapts existing evidence and prior guideline recommendations rather than generating new primary data; many recommendations rely on observational data or expert consensus where RCT evidence is limited, and supporting evidence tables are in online supplements rather than fully in the main text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000000678

Cites

435 of 435 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 1 Not valid · 237 Not checked · 38 Own results and interpretations

153 more claims

Create a free account to see all 276 claims and to verify the 356 references still open.

See all claims — free account
  • It may state two separate claims as one. 92
  • Probably not a substantial claim. 31

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 436 references

Research works printed but not linked: 35

  1. Grundy, SM, Stone, NJ, Bailey, AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–1143.
  2. 10.1161/cir.0000000000000580 · DOI · Paper page
  3. 10.1161/hyp.0000000000000065 · DOI · Paper page
  4. DeFilippis, AP, Young, R, McEvoy, JW, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38:598–608.
  5. 10.5888/pcd13.160211 · DOI · Paper page
  6. LeBlanc EL Patnode CD Webber EM et al. Draft evidence review for weight loss to prevent obesity-related morbidity and mortality in adults: behavioral interventions. Kaiser Permanente Research Affiliates Evidence-based Practice Center Kaiser Permanente Center for Health Research: Portland OR; 2018. AHRQ Publication No. 18-05239-EF-1. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/obesity-in-adults-interventions1. Accessed January 5 2019.
  7. 10.1161/circulationaha.109.924977 · DOI · Paper page
  8. 10.1161/cir.0000000000000625 · DOI · Paper page
  9. Chou R Dana T Blazina I et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force. Report No. 14-05206-EF-2. 2016. US Agency for Healthcare Research and Quality: Rockville MD. Available at: http://www.ncbi.nlm.nih.gov/books/NBK396415. Accessed January 5 2019.
  10. 10.1056/nejmoa0807646 · DOI · Paper page
  11. 10.1016/j.jacc.2016.05.084 · DOI
  12. 10.1016/j.jacc.2015.07.066 · DOI · Paper page
  13. 10.1001/jamacardio.2017.2498 · DOI
  14. 10.1093/eurheartj/ehy217 · DOI · Paper page
  15. 10.7326/m14-1281 · DOI · Paper page
  16. 10.1001/jamacardio.2016.5493 · DOI · Paper page
  17. 10.1016/j.jcmg.2017.01.030 · DOI · Paper page
  18. 10.1001/jama.2016.17020 · DOI · Paper page
  19. 10.1016/j.jcmg.2016.03.022 · DOI
  20. 10.1016/j.jacc.2015.08.035 · DOI · Paper page
  21. 10.1001/jama.2015.7515 · DOI
  22. 10.1001/jamacardio.2017.0944 · DOI
  23. 10.1016/j.jacc.2015.10.058 · DOI · Paper page
  24. 10.1161/hyp.0000000000000065 · DOI · Paper page
  25. 10.1056/nejm200101043440101 · DOI · Paper page
  26. 10.1016/j.mayocp.2013.10.030 · DOI · Paper page
  27. 10.1016/s2468-2667(17)30003-8 · DOI · Paper page
  28. Tobacco Use and Dependence Guideline Panel Treating Tobacco Use and Dependence: 2008 Update. Washington, DC: US Department of Health and Human Services, 2008.
  29. US Institute of Medicine Committee on Secondhand Smoke Exposure and Acute Coronary Events. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, DC: National Academies Press. 2010. Available at: http://www.ncbi.nlm.nih.gov/books/NBK219565. Accessed January 5, 2019.
  30. 10.1093/eurheartj/ehw106 · DOI · Paper page
  31. 10.7326/m16-0577 · DOI · Paper page
  32. 10.1161/circoutcomes.113.000690 · DOI · Paper page
  33. 10.1056/nejmsa1616035 · DOI · Paper page
  34. 10.7326/m15-0171 · DOI · Paper page
  35. 10.7326/m15-2113 · DOI · Paper page

Cited by

See all 4,536

Metadata

Authors
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Virani, S. S., Williams, K. A., Yeboah, J., & Ziaeian, B.
Affiliations
  • University of Alberta (CA)
  • Lay Representative.
  • ACC/AHA Task Force on Clinical Practice Guidelines Liaison.
  • ACC/AHA Representative.
  • Task Force Performance Measures Representative.
Venue
Circulation
Published
2019-09-10
Volume
140
Issue
11
Pages
e596-e646
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W4210347219
Cited by
4,536
References
436
Citations by year
2026: 273 · 2025: 725 · 2024: 880 · 2023: 834 · 2022: 752 · 2021: 547 · 2020: 424 · 2019: 91
FWCI
74.12
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
American Heart Association (17SDG33630113)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
primary prevention, cardiovascular disease, cardiovascular risk factors, hypertension, hyperlipidemia, diabetes mellitus, smoking, obesity, physical inactivity, cardiovascular risk assessment, cardiovascular disease prevention
MeSH terms
American Heart Association, Cardiology, Cardiovascular Diseases, Humans, Primary Prevention, United States, Practice Guidelines as Topic, Advisory Committees, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. https://app.cochat.ai/papers/10.1161/cir.0000000000000678
The paper
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Virani, S. S., Williams, K. A., Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/cir.0000000000000678

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.